Table 4.

Clinical characteristics of BP cases associated with IL-12/IL-23, IL-23, or IL-17 inhibitors.

Ref	Age/sex	Primary diagnosis	Past history	Biologics	The total dose (mg)	Time tobulla (weeks)	BP occurring site	Anti-BP180/BP230	Serum IgE	BP therapy	Outcome
(46)	75/F	Plaque psoriasis	ND	Ustekinumab	225	41	Trunk and extremities	Negative	1,906 U/ml	Methylprednisolone, clobetasol, dexchlorpheniramine, and zinc sulfate (unresponsive). Thus, dapsone was added.	CR
(47)	76/F	Psoriasis	Asthma, osteoporosis, and metabolic syndrome	Ustekinumab	ND	8	Trunk, extremities, head and soles	Negative	1,906 U/ml	Oral corticosteroids	CR
(48)	58/M	Psoriasis	Renal failure, hypertension, and hepatosteatosis	Ustekinumab	90	4	Axillary fossa and inguinal region, trunk and extremities	ND	ND	Topical mometasone furoate, clobetasol propionate	CR
(49)	58/M	Plaque psoriasis	Type 2 diabetes and thyroidectomy	Ustekinumab	90	4	Palms, soles, upper trunk and limbs	ND	ND	Systemic prednisolone and cyclosporine	CR
(50)	62/M	Plaque psoriasis	Hypertension and type 2 diabetes	Ustekinumab	225	40	Upper thighs, lower neck, and upper trunk	ND	ND	Topical corticosteroids	CR
(51)	63/M	Psoriatic onycho-pachydermo periostitis, pustular psoriasis	ND	Ustekinumab	360	76	Trunk and extremities	Anti-BP180: 32.9 U/ml	ND	Oral prednisolone	CR
(45)	76/M	Psoriasis	Diabetes mellitus, chronic heart failure, and atrial fibrillation	Guselkumab	ND	4	Lower limbs	Positive for both	ND	Oral corticosteroid	CR
(52)	65/F	Psoriasis	ND	Secukinumab	150	8 days	Upper limbs and the trunk	Positive but not specific	ND	Topical corticosteroids	CR

BP, bullous pemphigoid; IL, interleukin; Ref, reference; CR, complete remission; ND, not described; F, female; M, male.